ライフサイエンスコーパス: drug formulation

1 g, release and in vitro metabolism of a dual drug formulation.

2 rtant polymeric excipient frequently used in drug formulation.

3 irst generation NPs that largely facilitated drug formulation.

4 uced toxicity as compared to the nontargeted drug formulations.

5 ly one third of that achieved for the single drug formulations.

6 oART can enhance viral clearance over native drug formulations.

7 rker of extravasation potential of liposomal drug formulations.

8 ve produced long circulating and very stable drug formulations.

9 ence issues and, availability of appropriate drug formulations.

10 stry to establish the bioequivalence between drug formulations.

11 In a given GRIR drug formulation, accuracy, response time, and reversibi

12 rug-food interactions for specific drugs and drug formulations, additional avenues need to be explore

13 Amphiphilic drug formulation additives based on palmitic acid-modifi

14 ageous than a combination of targeted single drug formulations administered at the same drug ratio.

15 The resulting specific drug formulation agents render insoluble drugs water-sol

16 that showed a similar efficacy to free dual drug formulations and even enhanced anti-cancer effects

17 eparin, an extensively used anticoagulant in drug formulations and medical devices, is critical to en

18 re the suprachoroidal injection of different drug formulations and to characterize the safety and pha

19 aqueous solubility, which in turn influences drug formulation approaches.

20 pharmacoeconomic principles that drive oral drug formulation are discussed.

21 is translates to the clinic, where liposomal drug formulations are reported to exhibit higher efficac

22 sed to unambiguously chemically characterize drug formulations at these length scales.

23 l anatomy, challenges to nasal delivery, and drug/formulation considerations for nose to brain delive

24 ereas animals treated with the rapid-release drug formulation Cremophor EL (PTX-CrEL) or saline (cont

25 es in various applications (crystallography, drug formulation, etc.).

26 r drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK pho

27 Refinements in drug formulation have provided the ability to target dis

28 ly solution employing oils typically used in drug formulations, i.e., middle-chain triglycerides and

29 unts of active ingredients in pharmaceutical drug formulations, illicit drugs (methamphetamine, cocai

30 ential idea is to encapsulate the ophthalmic drug formulations in nanoparticles and to disperse these

31 In addition, it is not clear if drug formulation is a major factor in optimizing pharmac

32 Application of lipid-based nanocarriers in drug formulation is one approach to improve drug safety.

33 the availability of pediatric antiretroviral drug formulations, it proved feasible to deliver pediatr

34 Exosome-based drug formulations may be applied to a wide variety of di

35 s a result, potential sites in which topical drug formulations might be sequestered post-poration and

36 Following this, we evaluated two drug formulations of TRAIL (TNF-related apoptosis induci

37 c decision making, the issues of infant CML, drug formulation, pharmacokinetics, and adolescent compl

38 ost observed toxicities were attributable to drug formulation (polyoxyl 35 castor oil or hyperosmolar

39 In vivo we demonstrate that the pro-drug formulation reduces application site inflammation c

40 e range of contraceptive options, varying in drug formulation, route of delivery, and discrepancy bet

41 g adenosine concentration in blood serum and drug formulation samples.The herein described methodolog

42 achieved through topical application of the drug formulation START (0.9% sodium chloride, 1% Tween 8

43 for allowance or avoidance of antiarrhythmic drug formulation substitution are suggested.

44 The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Do

45 Many inhalable drug formulations suffer from low respirable fractions,

46 ell as rigorous determination of the optimal drug formulation to achieve maximum potency with minimum

47 cancer properties and DW-F5 as a forthcoming drug formulation to be evaluated as a chemotherapeutic a

48 wall include finding suitable excipients for drug formulation to enable drug release to a targeted le

49 beneficial in the design and optimization of drug formulations to treat recalcitrant nail disease.

50 oach to the rapid analysis of pharmaceutical drug formulations using hyphenated ion mobility spectrom

51 This drug formulation was effective within hours by first blo

52 f individual drugs between 3-in-1 and single drug formulations were eliminated.

53 maceutical screening of low-molecular-weight drug formulations with high selectivity over the formula

54 elease rate compared with the large-particle drug formulation, with area under concentration-time cur

55 s in the application of cyclodextrins to new drug formulations, with emphasis on the field of anesthe

56 The development of child-friendly drug formulations would need to be carried out in parall